iCAD/ICAD

$1.54

-3.14%
-
1D1W1MYTD1YMAX

About iCAD

iCAD, Inc. is a global medical technology company, which provides cancer detection and therapy solutions. The Company is focused on providing breast cancer detection solutions built on artificial intelligence (AI) that empowers radiologists to find cancers. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, and a range of high-performance, AI and computer-aided detection (CAD) systems and workflow solutions for 2D and 3D mammography, magnetic resonance imaging and computed tomography (CT). The Company’s Breast AI Suite offers a triple threat of clinically proven cancer detection, density assessment, and risk evaluation solutions, designed to accelerate discovery and improve outcomes. It also offers ProFound AI, a digital breast tomosynthesis (DBT) cancer detection and workflow solution.

Ticker

ICAD

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Dana Brown

Employees

67

Headquarters

Nashua, United States

iCAD Metrics

BasicAdvanced
$41.4M
Market cap
-
P/E ratio
-$0.19
EPS
1.34
Beta
-
Dividend rate
$41.4M
1.33823
$3.97
$1.05
208.12K
4.398
4.262
-15.06%
-20.52%
-19.23%
2.391
1.23
1.662
-12.54%
30.3%
-16.45%

What the Analysts think about iCAD

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
213.64% upside
High $9.00
Low $2.50
$1.54
Current price
$4.83
Average price target

iCAD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
42.55% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$4.7M
17.5%
Net income
$2M
-253.85%
Profit margin
42.55%
-230.92%

iCAD Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 193.75%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.15
-$0.07
-$0.05
$0.05
-
Expected
-$0.11
-$0.11
-$0.09
-$0.05
-$0.06
Surprise
31.35%
-36.36%
-44.44%
-193.75%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for iCAD stock?

iCAD (ICAD) has a market cap of $42.2M as of April 21, 2024.

What is the P/E ratio for iCAD stock?

The price to earnings (P/E) ratio for iCAD (ICAD) stock is 0 as of April 21, 2024.

Does iCAD stock pay dividends?

No, iCAD (ICAD) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next iCAD dividend payment date?

iCAD (ICAD) stock does not pay dividends to its shareholders.

What is the beta indicator for iCAD?

iCAD (ICAD) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the iCAD stock price target?

The target price for iCAD (ICAD) stock is $4.83, which is 213.64% above the current price of $1.54. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell iCAD stock

Buy or sell iCAD stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing